Title:
FUSED PYRIMIDINE DERIVATIVE AND APPLICATION THEREOF
Document Type and Number:
WIPO Patent Application WO/2023/227139
Kind Code:
A1
Abstract:
The invention relates to a novel fused pyrimidine compound as shown in general formula I, or a stereoisomer, pharmaceutically acceptable salt, solvate or prodrug thereof, and preparation methods and uses therefor. The meanings of R1, R2, A, Y, L, and n are provided the description. The invention further relates to an application of the compound and the pharmaceutically acceptable salt, solvate or prodrug thereof in the preparation of a drug for treating diseases caused by abnormally high ATR expression, in particular to the application of the compound in the preparation of a drug for treating and/or preventing hyperproliferative diseases, including but not limited to gastric cancer, liver cancer, colorectal cancer, ovarian cancer, pancreatic cancer etc.
More Like This:
Inventors:
ZHAO YANFANG (CN)
HOU YUNLEI (CN)
QI YINLIANG (CN)
YANG DEXIAO (CN)
TONG MINGHUI (CN)
XI ZHIGUO (CN)
HOU YUNLEI (CN)
QI YINLIANG (CN)
YANG DEXIAO (CN)
TONG MINGHUI (CN)
XI ZHIGUO (CN)
Application Number:
PCT/CN2023/106083
Publication Date:
November 30, 2023
Filing Date:
July 06, 2023
Export Citation:
Assignee:
UNIV SHENYANG PHARMACEUTICAL (CN)
3D BIOOPTIMA (CN)
3D BIOOPTIMA (CN)
International Classes:
C07D471/04; A61K31/5377; A61P35/00; C07D487/04; C07D519/00
Domestic Patent References:
| WO2007127183A1 | 2007-11-08 |
Foreign References:
| CN115466258A | 2022-12-13 | |||
| CN111057065A | 2020-04-24 | |||
| CN101511840A | 2009-08-19 |
Attorney, Agent or Firm:
CHINA SCIENCE PATENT & TRADEMARK AGENT LTD. (CN)
Download PDF: